(Total Views: 219)
Posted On: 02/12/2017 12:09:10 PM
Post# of 98289
![Avatar](https://investorshangout.com/images/ProfileImages/934136062_182_A_Dawgg 1 Two 10-baggers at the same time..jpg)
$BLFS. breakout candle. $2.07
Might pull back below upper bollie $1.92
Nasdaq CM
Website
BioLife Solutions Announces 2016 Revenue Growth of 28%
2017 Guidance Provided 1/12/17
100% x 100% Strong Buy
10 K/A 12/9/2016
Last 10 trades
Stock technical analysis
Shares Outstanding 12.88M
Float 6.3M
% Held by Insiders 51.44%
% Held by Institutions 3.40%
Shares Short 199.37k
Short Ratio 5.8
Short % of Float 6.04%
Shares Short (prior month) 208.77k
The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services.
Might pull back below upper bollie $1.92
Nasdaq CM
Website
BioLife Solutions Announces 2016 Revenue Growth of 28%
2017 Guidance Provided 1/12/17
100% x 100% Strong Buy
![850318709_barchart_logo1.jpg](http://investorshangout.com/images/MYImages/850318709_barchart_logo1.jpg)
10 K/A 12/9/2016
![1642481658_otc.jpeg](http://investorshangout.com/images/MYImages/1642481658_otc.jpeg)
Last 10 trades
Stock technical analysis
![895828223_stockta5.jpg](http://investorshangout.com/images/MYImages/895828223_stockta5.jpg)
Shares Outstanding 12.88M
Float 6.3M
% Held by Insiders 51.44%
% Held by Institutions 3.40%
Shares Short 199.37k
Short Ratio 5.8
Short % of Float 6.04%
Shares Short (prior month) 208.77k
The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)
Scroll down for more posts ▼